What are the recent financial highlights of AJANTA PHARMA LIMITED?

AJANTA PHARMA LIMITED recently reported a total revenue of ₹4,531.77 Cr and a net profit margin of 19.81%. These metrics reflect the company’s consistent financial performance.

What is the dividend yield of AJANTA PHARMA LIMITED?

AJANTA PHARMA LIMITED offers a dividend yield of 2.17%, with a dividend rate of ₹54.0 per share.

What are the key financial metrics of AJANTA PHARMA LIMITED?

Key financial metrics include a trailing P/E ratio of 33.557556, forward P/E of 24.194702, book value of ₹293.334, price-to-book ratio of 8.188788, and a market capitalization of ₹300.71 billion.

What does AJANTA PHARMA LIMITED do?

Ajanta Pharma Limited, a specialty pharmaceutical formulation company, together with its subsidiaries, develops, manufactures, and markets speciality pharmaceutical finished dosages. The company markets and serves various therapeutic segments, such as cardiology, antidiabetic, ophthalmology, dermatology, pain management, and respiratory areas. It also provides tablets, capsules, injectables, inhalers, ointments, creams, and liquids. The company serves in India, Africa, rest of Asia, the United States, and internationally. Ajanta Pharma Limited was founded in 1973 and is headquartered in Mumbai, India.

Loading...

₹ 0 0.00%

Loading... BSE: Loding... NSE: Ajantpharm

About

Loading... ^[1]

Website BSE NSE

Market Cap ₹ 0 Cr.
Current Price ₹ 0
High / Low ₹ 0 / 0
Stock P/E
Dividend Yield 0 %
ROE 0 %
EPS 0
P/B Ratio 0
Net Profit Margin 0 %
Debt to Equity 0
ROCE 0 %
Interest Coverage 0 %

Stock News - Ajantpharm

Latest updates related to Ajantpharm

Sr No.	Title	Sentiment
1	Ajanta Pharma's (NSE:AJANTPHARM) five-year earnings growth trails the impressive shareholder returns Simply Wall St	🔄
2	What Ajanta Pharma Limited's (NSE:AJANTPHARM) P/E Is Not Telling You Simply Wall St	🔄
3	Is Weakness In Ajanta Pharma Limited (NSE:AJANTPHARM) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects? Simply Wall St	🔄
4	With EPS Growth And More, Ajanta Pharma (NSE:AJANTPHARM) Makes An Interesting Case Simply Wall St	🔄
5	Ajanta Pharma Ltd Share Price Today, AJANTPHARM Share Price NSE, BSE Business Today	🔄
6	While insiders own 29% of Ajanta Pharma Limited (NSE:AJANTPHARM), private companies are its largest shareholders with 37% ownership Simply Wall St	🔄
7	Ajanta Pharma Limited (NSE:AJANTPHARM) Is About To Go Ex-Dividend, And It Pays A 1.8% Yield Simply Wall St	🔄
8	Ajanta Pharma (NSE:AJANTPHARM) stock performs better than its underlying earnings growth over last five years Simply Wall St	🔄
9	We Think Ajanta Pharma (NSE:AJANTPHARM) Can Manage Its Debt With Ease Simply Wall St	🔄

Peer Comparison

Macro Industry: Loading.. | Sector: Loading.. | Industry: Loading.. | Basic Industry: Loading..

Loading peers table...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Loading data...

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Loading Profit & Loss data...

Compounded Sales Growth
10 Years:
5 Years:
3 Years:
TTM:

Compounded Profit Growth
10 Years:
5 Years:
3 Years:
TTM:

Stock Price CAGR
10 Years:
5 Years:
3 Years:
1 Year:

Return on Equity
10 Years:
5 Years:
3 Years:
Last Year:

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Shareholding Pattern

Numbers in percentages

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Loading...

Loading...

Stock News - Ajantpharm

Peer Comparison

Quarterly Results

Profit & Loss

Balance Sheet

Cash Flows

Ratios

Shareholding Pattern

Delivery Data

Insider Data

Technical Data

Static Application Security Testing

Documents

Announcements

Annual reports

Credit ratings

Concalls

Explore More Stocks